TITLE:
Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)

CONDITION:
Small Cell Lung Cancer

INTERVENTION:
Diflomotecan (BN80915)

SUMMARY:

      This is a Phase II, open-label, multicenter, single-arm, exploratory "proof of concept"
      study. Diflomotecan (7 mg fixed dose) will be administered as a 20-minute IV infusion once
      every 3 weeks in patients with sensitive small cell lung cancer (SCLC) with progressive
      disease after first-line treatment with a platinum-based regimen.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Main Inclusion Criteria:

          -  Documented small cell lung cancer (SCLC)

          -  Measurable disease

          -  One line of previous chemotherapy, including any platinum analogue, and excluding any
             camptothecin analogues, with objective response and relapsed no less than 3 months

        Main Exclusion Criteria:

          -  Uncontrollable brain metastasis

          -  Treated with an investigational drug within 30 days
      
